Patents by Inventor Flavio Solca

Flavio Solca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190125751
    Abstract: The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an irreversible (2nd generation) EGFR TKI, each as described herein.
    Type: Application
    Filed: May 15, 2017
    Publication date: May 2, 2019
    Inventors: Flavio SOLCA, Mahmoud OULD KACI, Mark PETRONCZKI, Ulrike TONTSCH-GRUNT, Victoria ZAZULINA
  • Publication number: 20180360834
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: December 19, 2017
    Publication date: December 20, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Publication number: 20180346559
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • Publication number: 20180086744
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • Publication number: 20170312360
    Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 2, 2017
    Inventors: Louis Jean DENIS, Robert Michael LORENCE, Mehdi SHAHIDI, Flavio SOLCA
  • Publication number: 20170112835
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 27, 2017
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Publication number: 20170088609
    Abstract: The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an anti-IGF antibody, each as described herein.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 30, 2017
    Inventors: Flavio SOLCA, Ulrike WEYER-CZERNILOFSKY, Jin Kyung RHO, Jae Cheol LEE
  • Patent number: 9539258
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • Publication number: 20160101175
    Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventors: Louis DENIS, Robert Michael LORENCE, Mehdi SHAHIDI, Flavio SOLCA
  • Publication number: 20150272954
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Publication number: 20150265610
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Patent number: 9089571
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • Publication number: 20140341926
    Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Louis DENIS, Robert Michael LORENCE, Mehdi SHAHIDI, Flavio SOLCA
  • Patent number: 8877764
    Abstract: The present invention relates to a method of treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumor resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Flavio Solca
  • Patent number: 8828391
    Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Louis Denis, Robert Michael Lorence, Mehdi Shahidi, Flavio Solca
  • Publication number: 20140199298
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 17, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • Publication number: 20140194442
    Abstract: The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein.
    Type: Application
    Filed: January 12, 2012
    Publication date: July 10, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio Solca, Ulrich Guertler, Michael Sanderson, Ulrike Tontsch-Grunt, Irene Waizenegger
  • Patent number: 8722694
    Abstract: The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: May 13, 2014
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Thomas Metz, Flavio Solca, Birgit Jung, Anke Baum
  • Publication number: 20140066456
    Abstract: The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Pilar GARIN-CHESA, Flavio SOLCA
  • Publication number: 20140057898
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL